Floatz logo

Copanlisib

Prostate Cancer

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
59/ 100

Competitive context

513 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
Fluciclovine
NRG Oncology
Phase 4BB

View all 50 →

Same molecule, other indications

Copanlisib is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →